In the international pharmaceutical industry chain restructuring, drug research and development and manufacturing of some parts of the trend of continuous transfer to developing countries, China has become a key area of global pharmaceutical industry transfer due to its cost advantage, sufficient professional and technical personnel, rich production experience, and huge market potential. Therefore, the future expansion of the scale of preparation production will certainly drive the growth of China's pharmaceutical excipients market demand, and the growth of new pharmaceutical excipients will be more rapid.
According to the latest report released by Markets and Markets, the global pharmaceutical excipients market size is expected to increase from $7.9 billion in 2021 to $10.6 billion in 2026, with a CAGR of 5.8% during the forecast period.
As a high-tech enterprise specializing in the manufacture of pharmaceutical excipients "plant hollow capsules", we are committed to providing high-quality plant hollow capsules for the global pharmaceutical industry.
Our plant hollow capsules are a kind of natural pharmaceutical excipients, extracted from plants without any animal ingredients, which can meet the needs of people with vegetarian culture and special religious groups such as Muslims and Jews. At the same time, it has the advantages of good universality, stable physical and chemical properties, no chemical residue, no bacterial microbial contamination, etc.
Recently, Zhang Jinsong, vice mayor of Tianmen City, and his delegation visited our Hebei production base for field inspection. The annual production capacity of the base is 1.6 billion capsules, and the products are mainly sold to Europe and America. In the seminar, both sides discussed the market space, scientific research technology and manufacturing process of the plant hollow capsule project. Meanwhile, the industry development trend of biomedicine, new materials and intelligent manufacturing was focused on.
The biopharmaceutical industry is a traditional industrial cluster in Tianmen City, which has more than 40 biopharmaceutical enterprises above the scale, with an annual output value of more than 6 billion yuan, covering such fields as pharmaceutical intermediates, chemical APIs and preparations, skin topical drugs, biopharmaceuticals, medical epidemiology, fine chemicals, etc. At present, we have introduced and cultivated such key enterprises as Yitai Pharmaceutical, Huastong Pharmaceutical, Renfu Narita Pharmaceutical, Yanan Pharmaceutical, Runchi Environmental Protection, Upp Biological and other key enterprises.
The visit was successfully concluded, and both sides will further strengthen cooperation in the future to accelerate the promotion and application of the plant hollow capsule project and actively promote the upgrading of natural pharmaceutical excipients in the industry.
